Workflow
辉瑞(PFE)
icon
搜索文档
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Prnewswire· 2025-12-17 19:45
"Building on the recent U.S. approval for cisplatin-ineligible patients living with MIBC, these positive EV-304 findings reinforce the potential of PADCEV plus pembrolizumab to improve survival outcomes for a broad population of patients living with muscle-invasive bladder cancer. Together with the EV-303 data, these results strengthen the evidence supporting this combination regimen as a treatment option for patients regardless of cisplatin eligibility. We are committed to bringing forth much-needed advanc ...
药物受理最新动态:Pfizer Inc.硫酸瑞美吉泮口崩片补充申请获受理
新浪财经· 2025-12-17 14:20
来源:新浪财经-鹰眼工作室 国家药品监督管理局药品审评中心数据显示,2025年12月17日,Pfizer Inc.的硫酸瑞美吉泮口崩片申请 已获受理,受理号为JXHB2500169。 股东名称持股比例认缴出资额认缴出资日期首次持股日期美国晖致企业公司100%8040万美元2017年11 月30日2023年06月09日 声明:市场有风险,投资需谨慎。 本文为AI大模型基于第三方数据库自动发布,任何在本文出现的信 息(包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等)均只作为参考,不构成 个人投资建议。受限于第三方数据库质量等问题,我们无法对数据的真实性及完整性进行分辨或核验, 因此本文内容可能出现不准确、不完整、误导性的内容或信息,具体以公司公告为准。如有疑问,请联 系biz@staff.sina.com.cn。 受理号JXHB2500169药品名称硫酸瑞美吉泮口崩片药品类型化药申请类型补充申请注册分类2.4企业名 称Pfizer Inc.;Catalent Pharma Solutions Limited;承办日期2025年12月17日 天眼查数据显示,Pfizer Inc.成立日期1989年 ...
11月新增非农谈不上强劲:环球市场动态2025年12月17日
中信证券· 2025-12-17 10:37
宏观经济与美联储政策 - 美国2025年11月新增非农就业人数6.4万人,高于预期的5万人,但失业率升至4.6%,高于预期的4.5%[5] - 美国2025年10月非农就业人数初值为减少10.5万人,创五年以来最大降幅[5] - 美联储主席鲍威尔认为11月新增非农就业“谈不上强劲”,若12月失业率不继续上升,政策利率仍被视为“well positioned”[5] - 市场预期美联储将在2026年1月暂停降息,剩余两次议息会议可能还有一次25个基点的降息[5] 全球股市表现 - 美股三大指数周二(12月16日)个别发展,道指跌0.62%至48,114.3点,标普500跌0.24%至6,800.3点,纳指涨0.23%至23,111.5点[7][8] - 欧洲股市普遍下跌,英国富时100指数跌0.68%,德国DAX指数跌0.63%,法国CAC 40指数跌0.23%[7][8] - 亚太股市周二跌多涨少,韩国KOSPI指数跌2.2%至3,999.1点,跌幅居前;越南证交所指数涨2.0%至1,679.2点,涨幅居前[21][22] - 港股周二大跌,恒生指数跌1.54%至25,235点,恒生科技指数跌1.74%[10] - A股周二集体下挫,沪指跌1.11%报3,824点,深证成指跌1.51%,创业板指跌2.1%[15] 外汇与大宗商品市场 - 美元指数周二(12月16日)收于98.15,单日下跌0.2%,年初至今累计下跌9.5%[26] - 纽约期油(WTI)周二收于每桶55.3美元,单日下跌2.7%,盘中自2021年以来首次跌破55美元/桶[26][27] - 纽约期金周二收于每盎司4,304.5美元,单日微跌0.1%,年初至今累计上涨63.0%[26] 固定收益市场 - 美国国债收益率周二普遍下跌,2年期收益率下降1.5个基点至3.49%,10年期收益率下降2.7个基点至4.15%[29][30] - 亚洲债券市场整体平静,投资级美元债券利差维持在61.5个基点不变[30] 重点公司及行业观点 - 中信证券看好金融科技公司Robinhood,认为其预测市场业务有望在未来1-2年带来数亿美元量级的收入[8] - 中信证券认为市场对雅迪控股在“新新国标”下的担忧过度,公司有能力逆势提升市场份额[13] - 中信证券指出中国消费市场呈“K型复苏”,高端消费(如奢侈品、高端旅游)表现优于大众消费[19] - 中信里昂看好澳大利亚公司Orica,其2026财年开局强劲,股价年内已上涨47%[23]
Wall Street ends mixed, healthcare and energy stocks weigh on S&P
The Economic Times· 2025-12-17 09:54
A separate report on Tuesday showed retail sales were flat in October, just below an estimate of economists polled by Reuters calling for a rise of 0.1%. Analysts flagged the likelihood of the figures being distorted by slow data collection due to a recent government shutdown."This is all fairly old news at this point. Most data points are being viewed in the lens of what they are going to do to the Fed, and the data you got today isn't likely to move the needle," said Mark Hackett, chief market strategist ...
Tilray Brands, Pfizer, Netflix, Lennar Corp. And Tesla: Why These 5 Stocks Are On Investors' Radars Today - Lennar (NYSE:LEN), Netflix (NASDAQ:NFLX)
Benzinga· 2025-12-17 09:09
The U.S. labor market showed further signs of cooling in November as nonfarm payrolls rose by 64,000, only modestly above expectations but still weak by historical standards, while the unemployment rate unexpectedly climbed to 4.6%,The Dow Jones Industrial Average fell 0.6% to 48,114.26, while the S&P 500 dropped 0.2% to 6,800.26. The Nasdaq rose 0.2% to 23,111.46.These are the top stocks that gained the attention of retail traders and investors through the day.Tilray Brands Inc. (NASDAQ:TLRY) Tilray Brands ...
Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast
The Motley Fool· 2025-12-17 06:43
公司股价与市场表现 - 辉瑞公司股价于2025年12月16日收于25.53美元,当日下跌3.40%(或0.90美元)[2] - 当日交易量达到1.081亿股,较其三个月平均交易量高出近60% [2] - 公司当前市值约为1500亿美元,股息收益率为6.51% [2] 业绩指引与财务预测 - 公司下调了2025年营收指引至620亿美元,此前指引区间为610亿至640亿美元 [5] - 公司重申2025年调整后每股收益指引为3.00至3.15美元 [5] - 公司预计2026年营收将基本持平,预期区间为595亿至625亿美元,主要因新冠药物收入下降及专利到期 [5] 增长挑战与战略应对 - 公司增长面临挑战,原因是新冠相关现金流萎缩,且并购押注需要时间才能产生效益 [1] - 新冠产品收入侵蚀速度快于预期 [3] - 公司正在削减成本并将收益投入研发,例如近期收购了一家专注于肥胖和心脏代谢疾病的生物制药公司 [6] - 公司计划于2026年推进肥胖药物试验,但新举措需要时间才能见效 [6] 行业影响 - 辉瑞的业绩评论影响了其同行,默克公司股价下跌1.99%,强生公司股价下跌2.27% [4] - 投资者正在重新评估大型制药公司的盈利能力 [4]
S&P Slips After Jobs Report as Treasury Yields Rise | Closing Bell
Youtube· 2025-12-17 05:40
And right now we are 2 minutes away from the end of the trading day. Romaine Bostick alongside Katie Greifeld, taking you through to that closing bell with the global simulcast. Carol Massar Tim Stenovec.They join us from the radio room as we welcome all of our audiences across all of our platforms, including our partnership with YouTube. An interesting day in the market. But Carol, I do want to start with that breaking news that we got a little while ago.Just a few minutes ago here, Warner Brothers Discove ...
Pfizer Q4 2026 Financial Guidance (NYSE:PFE) 2025-12-16
Seeking Alpha· 2025-12-17 03:53
新闻内容分析 - 提供的文档内容不包含任何实质性的新闻、事件、财报或行业信息 文档内容仅为技术性提示 要求用户启用浏览器Javascript和Cookies或禁用广告拦截器以继续访问 [1]
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Seeking Alpha· 2025-12-17 03:39
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...
Freddie Mac Names Kenny M. Smith as Next Chief Executive
WSJ· 2025-12-17 03:38
Smith is expected to start the role on Wednesday and would also serve as a board member, the government-backed mortgage provider said. ...